Table 3.

Crude and adjusted odds ratios (95% CI) of increased 10-year risk scores (≥5%) for atherosclerotic cardiovascular disease in postmenopausal women according to oral glucose tolerance status.

	NGT	IGT	IPH
Scenario 1†
No. of subjects (10-yr ASCVD risk score ≥5% vs <5%)	15/121	43/171	25/53
Model 1	1.0	2.03 (1.08–3.82)*	3.81 (1.86–7.79)***
Model 2	1.0	1.92 (1.01–3.62)*	3.35 (1.62–6.92)**
Model 3	1.0	1.96 (0.98–3.89)	3.28 (1.47–7.36)**
Scenario 2‡
No. of subjects (10-yr ASCVD risk score ≥5% vs <5%)	15/121	43/171	56/22
Model 1	1.0	2.03 (1.08–3.82)*	20.53 (9.91–42.55)***
Model 2	1.0	1.89 (0.99–3.58)	19.03 (9.08–39.90)***
Model 3	1.0	1.87 (0.93–3.78)	26.74 (11.47–62.34)***

Data are expressed odds ratios (95% CI).

Model 1, no adjustment; Model 2, further adjusted for BMI; Model 3, further adjusted for physical inactivity score, Log ALT, serum Cr, hypertension treatment (yes vs no), and Hormone replacement (yes vs no).

ALT = alanine aminotransferase, ASCVD = atherosclerotic cardiovascular disease, BMI = body mass index, CI = confidence intervals, Cr = creatinine, IGT = impaired glucose tolerance, IPH = isolated postchallenge hyperglycemia, Log ALT = logarithmic transformation of ALT (in U/L), NGT = normal glucose tolerance.

^†Scenario 1: subjects with IPH were not designated as patients of diabetes mellitus while performing ASCVD risk estimation.

^‡Scenario 2: subjects with IPH were designated as patients of diabetes mellitus while performing ASCVD risk estimation.

^*P < .05 versus NGT by logistic regression analysis.

^**P < .01 versus NGT by logistic regression analysis.

^***P < .0001 versus NGT by logistic regression analysis.